VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst. 2006 Nov 01; 98(21):1558-70.
View in:
PubMed
subject areas
Analysis of Variance
Angiogenesis Inhibitors
Animals
Antibodies, Monoclonal
Antineoplastic Agents
Cell Line, Tumor
Enzyme-Linked Immunosorbent Assay
Female
Humans
Immunoblotting
Immunohistochemistry
Immunoprecipitation
In Situ Hybridization
In Situ Nick-End Labeling
Mice
Neovascularization, Pathologic
Ovarian Neoplasms
Receptor, EphA2
Reverse Transcriptase Polymerase Chain Reaction
Vascular Endothelial Growth Factor A
authors with profiles
GARY E GALLICK
ROSEMARIE SCHMANDT
ANIL K SOOD
LINGEGOWDA SELANERE MANGALA